Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments
Séverine Coquerelle
(1, 2)
,
Meryl Darlington
(1)
,
Morgane Michel
(1, 3)
,
Manon Durand
(1)
,
Isabelle Borget
(4)
,
Sandrine Baffert
(5)
,
Patricia Marino
(6)
,
Lionel Perrier
(7)
,
Isabelle Durand-Zaleski
(1, 2, 8)
1
URC Eco -
Unité de recherche clinique en économie de la santé d'Ile-de-France
2 CRESS (U1153 / UMR_A 1125) - Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques
3 ECEVE (U1123 / UMR_S_1123) - Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables
4 Etudes et Recherche en économie de la santé
5 CHU Rothschild [AP-HP]
6 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
7 GATE Lyon Saint-Étienne - Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne
8 Hôpital Henri Mondor
2 CRESS (U1153 / UMR_A 1125) - Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques
3 ECEVE (U1123 / UMR_S_1123) - Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables
4 Etudes et Recherche en économie de la santé
5 CHU Rothschild [AP-HP]
6 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
7 GATE Lyon Saint-Étienne - Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne
8 Hôpital Henri Mondor
Patricia Marino
- Fonction : Auteur
- PersonId : 21175
- IdHAL : patricia-marino
Lionel Perrier
- Fonction : Auteur
- PersonId : 15600
- IdHAL : lionel-perrier
- ORCID : 0000-0003-4487-8723
- IdRef : 060772239
Résumé
Objectives: We evaluated how next generation sequencing (NGS) can modify care pathways in an observational impact study in France.Methods: All patients with lung cancer, colorectal cancer, or melanoma who had NGS analyses of somatic genomic alterations done in 1 of 7 biomolecular platforms certified by the French National Cancer Institute (INCa) between 2013 and 2016 were eligible. We compared patients' pathways before and after their NGS results. Endpoints consisted of the turnaround time in obtaining results, the number of patients with at least 1 genomic alteration identified, the number of actionable alterations, the impact of the genomic multidisciplinary tumor board on care pathways, the number of changes in the treatment plan, and the survival outcome up to 1 year after NGS analyses.Results: 1213 patients with a request for NGS analysis were included. NGS was performed for 1155 patients, identified at least 1 genomic alteration for 867 (75%), and provided an actionable alteration for 614 (53%). Turnaround time between analyses and results was on average 8 days (Min: 0; Max: 95) for all cancer types. Before NGS analysis, 33 of 614 patients (5%) were prescribed a targeted therapy compared with 54 of 614 patients (8%) after NGS analysis. Proposition of inclusion in clinical trials with experimental treatments increased from 5% (n = 31 of 614) before to 28% (n = 178 of 614) after NGS analysis. Patients who benefited from a genotype matched treatment after NGS analysis tended to have a better survival outcome at 1 year than patients with nonmatched treatment: 258 days (±107) compared with 234 days (±106), (P = .41).Conclusions: NGS analyses resulted in a change in patients' care pathways for 20% of patients (n = 232 of 1155).
Domaines
Economies et financesFormat du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments
|
Résumé |
en
Objectives: We evaluated how next generation sequencing (NGS) can modify care pathways in an observational impact study in France.Methods: All patients with lung cancer, colorectal cancer, or melanoma who had NGS analyses of somatic genomic alterations done in 1 of 7 biomolecular platforms certified by the French National Cancer Institute (INCa) between 2013 and 2016 were eligible. We compared patients' pathways before and after their NGS results. Endpoints consisted of the turnaround time in obtaining results, the number of patients with at least 1 genomic alteration identified, the number of actionable alterations, the impact of the genomic multidisciplinary tumor board on care pathways, the number of changes in the treatment plan, and the survival outcome up to 1 year after NGS analyses.Results: 1213 patients with a request for NGS analysis were included. NGS was performed for 1155 patients, identified at least 1 genomic alteration for 867 (75%), and provided an actionable alteration for 614 (53%). Turnaround time between analyses and results was on average 8 days (Min: 0; Max: 95) for all cancer types. Before NGS analysis, 33 of 614 patients (5%) were prescribed a targeted therapy compared with 54 of 614 patients (8%) after NGS analysis. Proposition of inclusion in clinical trials with experimental treatments increased from 5% (n = 31 of 614) before to 28% (n = 178 of 614) after NGS analysis. Patients who benefited from a genotype matched treatment after NGS analysis tended to have a better survival outcome at 1 year than patients with nonmatched treatment: 258 days (±107) compared with 234 days (±106), (P = .41).Conclusions: NGS analyses resulted in a change in patients' care pathways for 20% of patients (n = 232 of 1155).
|
Auteur(s) |
Séverine Coquerelle
1, 2
, Meryl Darlington
1
, Morgane Michel
1, 3
, Manon Durand
1
, Isabelle Borget
4
, Sandrine Baffert
5
, Patricia Marino
6
, Lionel Perrier
7
, Isabelle Durand-Zaleski
1, 2, 8
1
URC Eco -
Unité de recherche clinique en économie de la santé d'Ile-de-France
( 506958 )
- Galerie B1 - 3ème étage - 1 Place du Parvis Notre Dame 75004 Paris.
- France
2
CRESS (U1153 / UMR_A 1125) -
Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques
( 1002409 )
- Hôtel-Dieu - 1 place du Parvis Notre-Dame - 75004 Paris
- France
3
ECEVE (U1123 / UMR_S_1123) -
Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables
( 1005005 )
- 48 Boulevard Sérurier 75019 Paris
- France
4
Etudes et Recherche en économie de la santé
( 554076 )
- France
5
CHU Rothschild [AP-HP]
( 453714 )
- 5 rue Santerre
75571 Paris cedex 12
- France
6
SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD -
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
( 541536 )
- Faculté de Médecine - Site Timone - 27 Bd Jean Moulin 13385 Marseille Cedex 05.
- France
7
GATE Lyon Saint-Étienne -
Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne
( 102550 )
- 93, chemin des Mouilles 69130 Écully
6, rue Basse des Rives 42023 Saint-Étienne cedex 02
- France
8
Hôpital Henri Mondor
( 29301 )
- Créteil
- France
|
Licence |
Paternité - Pas d'utilisation commerciale
|
Langue du document |
Anglais
|
Nom de la revue |
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Date de publication |
2020
|
Volume |
23
|
Numéro |
7
|
Page/Identifiant |
pp. 898-906
|
Domaine(s) |
|
Collaboration/Projet |
|
Mots-clés |
en
NGS, clinical practice, oncology, somatic alterations.
|
DOI | 10.1016/j.jval.2020.03.005 |
PII | S1098-3015(20)30181-9 |
Pubmed Id | 32762992 |
Origine :
Fichiers produits par l'(les) auteur(s)
Loading...